Johnson & Johnson (J&J) has formally appealed a federal judge’s ruling that drugmakers cannot unilaterally implement a 340B rebate model—a [...] …
Category: Regulatory
The Health Resources and Services Administration (HRSA) recently reinstated eight Sagebrush sites into the 340B program—just one day before a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.’s eagerly anticipated first take on the 340B drug discount [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A federal district judge today upheld the Department of Health and Human Services’ (HHS) authority to preapprove 340B rebate models, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Health Resources and Services Administration (HRSA) on Tuesday rolled out new grant terms that require federally qualified health centers [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Three drugmakers and a drug industry tech firm are urging a federal appeals court to overturn a ruling that blocked [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
President Donald Trump’s recent executive order directing federal agencies to pursue “most favored nation” (MFN) pricing for prescription drugs could [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A national 340B community health center organization, which has faced criticism for its partnership with a powerful drug industry trade [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A major North Carolina health system has sued insurers Aetna Health and Humana for allegedly underpaying for 340B drugs purchased [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A federal appellate court in Washington, D.C. is fast-tracking Novartis and Bristol Myers Squibb’s (BMS) appeal of a lower court [...] …